HUTCHMED (Hutchison China MediTech)
Hong Kong, China

HUTCHMED (Hutchison China MediTech), a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

Investment Perspective

The China regulator has approved Hutchison China MediTech’s (Chi-Med’s) second internally discovered cancer drug, surufatinib (brand name Sulanda) for the treatment of epNET (non-pancreatic [extra-pancreatic] neuroendocrine tumours). Sulanda will be Chi-Med’s first unpartnered oncology drug launch in China, with potential for a label extension in pancreatic NET (pNET) later in 2021. Surufatinib is also on track to become Chi-Med’s first marketed drug in the US with the recent initiation of a rolling NDA submission for advanced NETs. The totality of the clinical data package shows a significant benefit to NET patients irrespective of tumour origin; with surufatinib addressing a major unmet need it has the potential to be the first global treatment option for NETs. Our valuation is increased to £6.45/share or $41.94/ADS.

Market information



Transitioning to a global oncology player
Lighthouse | 05 Mar 2021
China approval clears Sulanda in epNET
Update | 04 Jan 2021
Canada Pension Plan invests $100m at $30 per ADS
Lighthouse | 17 Nov 2020

Recent News

FY20 results & business update
04 Mar 2021
Savolitinib clinical data to be presented at virtual WCLC
14 Jan 2021
Strategic partnership with Inmagene for drug candidate portfolio for immunological diseases
11 Jan 2021
China approval of surufatinib in epNET
30 Dec 2020